Bone Metastases — BAY88-8223, Does Response Study in HRPC Patients
Citation(s)
A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin®) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients